University Division of Anaesthesia, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Box 93, Hills Road, Cambridge CB2 2QQ, UK.
Neurocrit Care. 2009;11(2):158-64. doi: 10.1007/s12028-009-9217-9. Epub 2009 Apr 29.
In order to identify whether low-dose (1 microg) tetracosactide (Synacthen) testing may be preferable to high-dose (250 microg) testing in the diagnosis of adrenal insufficiency in traumatic brain injury (TBI), as suggested by studies in other forms of critical illness.
We retrospectively reviewed the results of modified tetracosactide tests (involving administration of both low-dose and high-dose tetracosactide) conducted for clinical indications in patients in a neurocritical care unit within 10 days of TBI. Sixty-three modified tests were included and cortisol concentrations before and after administration of tetracosactide were extracted from the hospital records. Data were also extracted regarding hemodynamic response to empirical corticosteroid therapy, based on rapid weaning from vasoactive drugs.
Cortisol increments at 30 and 60 min following tetracosactide correlated well in the low-dose test (r(2) = 0.875, P < 0.0001). The mean cortisol concentration was 581 nmol/l at 30 min and 556 nmol/l at 60 min in the low-dose test. Cortisol increments following low-dose and high-dose testing correlated well overall (r(2) = 0.839, P < 0.0001), but results were discordant in 27 of 63 cases (43%) when the same diagnostic threshold was used. ROC curve analysis showed that both tests performed poorly in identifying hemodynamic steroid responsiveness (AUC 0.553 and 0.502, respectively).
In the low-dose tetracosactide test, it is sufficient to determine cortisol concentrations at baseline and at 30 min. Low-dose and high-dose tests give discordant results in a significant proportion of cases when using the same diagnostic threshold. Neither test can be used to guide the initiation of corticosteroid therapy in acute TBI.
为了确定低剂量(1 微克)促皮质素(Synacthen)检测是否优于高剂量(250 微克)检测,以诊断创伤性脑损伤(TBI)中的肾上腺功能不全,正如其他形式的危重病研究所示。
我们回顾性分析了神经重症监护病房患者在 TBI 后 10 天内根据临床指征进行的改良促皮质素试验(涉及低剂量和高剂量促皮质素的给药)的结果。纳入了 63 项改良试验,并从医院记录中提取了促皮质素给药前后的皮质醇浓度。还根据血管活性药物快速撤药,提取了基于经验性皮质类固醇治疗的血流动力学反应数据。
低剂量试验中,促皮质素后 30 和 60 分钟的皮质醇增量相关性良好(r²=0.875,P<0.0001)。低剂量试验中,30 分钟时皮质醇浓度为 581 nmol/L,60 分钟时为 556 nmol/L。低剂量和高剂量检测总体上相关性良好(r²=0.839,P<0.0001),但当使用相同的诊断阈值时,63 例中有 27 例(43%)结果不一致。ROC 曲线分析显示,两种检测方法在识别血流动力学类固醇反应性方面均表现不佳(AUC 分别为 0.553 和 0.502)。
在低剂量促皮质素试验中,确定基线和 30 分钟时的皮质醇浓度就足够了。当使用相同的诊断阈值时,低剂量和高剂量试验在很大一部分病例中得出不一致的结果。两种检测方法均不能用于指导急性 TBI 中皮质类固醇治疗的启动。